← View Portfolio
Passage is developing gene therapies for CNS-targeted rare diseases.
Passage Bio (PASG)
IPO February 2020
Passage Bio Closes $110 Million Series B Financing
Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases